Sarasin & Partners LLP Sells 49,029 Shares of Merck & Co., Inc. $MRK

Sarasin & Partners LLP lowered its holdings in Merck & Co., Inc. (NYSE:MRK) by 6.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 736,662 shares of the company’s stock after selling 49,029 shares during the period. Sarasin & Partners LLP’s holdings in Merck & Co., Inc. were worth $94,661,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Kingdom Financial Group LLC. purchased a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $25,000. Prosperity Bancshares Inc purchased a new position in Merck & Co., Inc. in the 4th quarter worth approximately $26,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth $26,000. IFC & Insurance Marketing Inc. bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth $31,000. Finally, High Note Wealth LLC raised its position in shares of Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on MRK shares. JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Scotiabank raised their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research report on Tuesday, June 30th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Finally, Morgan Stanley upped their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Thirteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average target price of $134.56.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst price-target increase: Guggenheim raised its Merck price target from $145 to $146 and maintained a Buy rating, implying meaningful upside from the referenced share price. This reinforces positive Wall Street sentiment. Benzinga
• Positive Sentiment: Keytruda gains another approval: Health Canada approved Keytruda with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer, expanding the drug’s use and potentially supporting sales before its major patent expirations. Health Canada approves Keytruda treatment
• Positive Sentiment: Pipeline and post-Keytruda strategy: Merck’s second-quarter commentary highlighted new product launches, pipeline progress and efforts to diversify into areas including vaccines, infectious diseases, hematology, cardiopulmonary disease and obesity. The company also raised its 2026 sales outlook, improving confidence in near-term execution. MRK Q2 earnings call
• Neutral Sentiment: Dividend comparison: Merck’s latest results have renewed debate over whether it offers a better income opportunity than Pfizer. The discussion may attract dividend-focused investors, but it does not represent a new company-specific catalyst. Pfizer or Merck dividend comparison
• Negative Sentiment: Keytruda patent risk remains central: Keytruda is approaching a significant patent cliff beginning in 2028. Merck is accelerating acquisitions and partnerships to offset the eventual revenue decline, but those investments can pressure earnings and increase execution risk. Merck is racing beyond Keytruda
• Negative Sentiment: Mixed pipeline development: Merck discontinued tulisokibart development in systemic sclerosis-associated interstitial lung disease, although the drug continues to be evaluated in other indications. The setback highlights clinical-development risk as Merck builds its post-Keytruda portfolio. MSD anti-TL1A trial update

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock opened at $128.27 on Friday. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $135.05. The stock has a market capitalization of $316.81 billion, a price-to-earnings ratio of 102.62, a price-to-earnings-growth ratio of 5.14 and a beta of 0.19. The company has a fifty day moving average of $123.78 and a 200-day moving average of $119.04. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts expect that Merck & Co., Inc. will post 2.72 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.